Literature DB >> 32065160

Humanized NOG Mice for Intravaginal HIV Exposure and Treatment of HIV Infection.

Anna H F Andersen1, Stine S F Nielsen2, Rikke Olesen2, Katharina Mack3, Frederik Dagnæs-Hansen4, Niels Uldbjerg5, Lars Østergaard2, Ole S Søgaard2, Paul W Denton6, Martin Tolstrup2.   

Abstract

Humanized mice provide a sophisticated platform to study human immunodeficiency virus (HIV) virology and to test antiviral drugs. This protocol describes the establishment of a human immune system in adult NOG mice. Here, we explain all the practical steps from isolation of umbilical cord blood derived human CD34+ cells and their subsequent intravenous transplantation into the mice, to the manipulation of the model through HIV infection, combination antiretroviral therapy (cART), and blood sampling. Approximately 75,000 hCD34+ cells are injected intravenously into the mice and the level of human chimerism, also known as humanization, in the peripheral blood is estimated longitudinally for months by flow cytometry. A total of 75,000 hCD34+ cells yields 20%-50% human CD45+ cells in the peripheral blood. The mice are susceptible to intravaginal infection with HIV and blood can be sampled once weekly for analysis, and twice monthly for extended periods. This protocol describes an assay for quantification of plasma viral load using droplet digital PCR (ddPCR). We show how the mice can be effectively treated with a standard-of-care cART regimen in the diet. The delivery of cART in the form of regular mouse chow is a significant refinement of the experimental model. This model can be used for preclinical analysis of both systemic and topical pre-exposure prophylaxis compounds as well as for testing of novel treatments and HIV cure strategies.

Entities:  

Year:  2020        PMID: 32065160     DOI: 10.3791/60723

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  5 in total

1.  CD45: a critical regulator in immune cells to predict severe and non-severe COVID-19 patients.

Authors:  Mingming Jin; Nannan Shi; Meng Wang; Chunzi Shi; Shengjie Lu; Qing Chang; Shuang Sha; Yun Lin; Yingmin Chen; Hui Zhou; Kaiyi Liang; Xuyuan Huang; Yuxin Shi; Gang Huang
Journal:  Aging (Albany NY)       Date:  2020-10-16       Impact factor: 5.682

Review 2.  Droplet digital PCR of viral ‎DNA/RNA, current progress, challenges, and future perspectives.

Authors:  Amir Asri Kojabad; Mahdieh Farzanehpour; Hadi Esmaeili Gouvarchin Galeh; Ruhollah Dorostkar; Ali Jafarpour; Masoumeh Bolandian; Majid Mirzaei Nodooshan
Journal:  J Med Virol       Date:  2021-03-11       Impact factor: 20.693

3.  Protocol for generating human immune system mice and hydrodynamic injection to analyze human hematopoiesis in vivo.

Authors:  Deshan Ren; Wei Liu; Shuai Ding; Yan Li
Journal:  STAR Protoc       Date:  2022-03-03

4.  CD169 (Siglec-1) as a Robust Human Cell Biomarker of Toll-Like Receptor 9 Agonist Immunotherapy.

Authors:  Stine Sofie Frank Lende; Marie Høst Pahus; Ida Monrad; Rikke Olesen; Anna R Mahr; Line K Vibholm; Lars Østergaard; Ole Schmeltz Søgaard; Anna Halling Folkmar Andersen; Paul W Denton; Martin Tolstrup
Journal:  Front Cell Infect Microbiol       Date:  2022-07-05       Impact factor: 6.073

5.  Comparable human reconstitution following Cesium-137 versus X-ray irradiation preconditioning in immunodeficient NOG mice.

Authors:  Anna Halling Folkmar Andersen; Stine Sofie Frank Nielsen; Rikke Olesen; Jakob Le Fèvre Harslund; Ole Schmeltz Søgaard; Lars Østergaard; Paul W Denton; Martin Tolstrup
Journal:  PLoS One       Date:  2020-10-29       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.